An observational study in Mantle Cell Lymphoma, sponsored by Fondazione Italiana Linfomi - ETS. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Fondazione Italiana Linfomi - ETS · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Lymphoma, Mantle-Cell by Fondazione Italiana Linfomi - ETS — 3 open to participants now, 5 under way, none of them phase 3. Lymphoma, Mantle-Cell · Fondazione Italiana Linfomi - ETS.
Among the 12 studies in Lymphoma, Mantle-Cell by Fondazione Italiana Linfomi - ETS, this one is the only one that started in 2027, is one of 3 observational ones, and was the 12th registered.
1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 154 are open to participants now.
Browse Lymphoma, Mantle-Cell studies →3 of the 12 studies in Lymphoma, Mantle-Cell by Fondazione Italiana Linfomi - ETS are open now, in 1 country. Recruiting first, the newest first:
Fondazione Italiana Linfomi - ETS · Sites in Italy
Ages 18+
Fondazione Italiana Linfomi - ETS · Sites in Italy
Ages 70+
By country, each count listing its studies:
Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 100 across 77 observational studies indexed under Lymphoma, Mantle-Cell.
Median enrollment 49 across the 9 interventional studies, 200 across the 3 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fondazione Italiana Linfomi - ETS is the lead sponsor of 92 studies on the registry; 24 are open to participants now.
1 of the studies in Lymphoma, Mantle-Cell by Fondazione Italiana Linfomi - ETS that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05249959Fondazione Italiana Linfomi - ETSConsolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Lymphoma, Mantle-Cell by Fondazione Italiana Linfomi - ETS, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Mantle cell lymphoma (MCL) is a subtype of B-cell non-Hodgkin lymphoma (B-NHL), characterized by a heterogeneous clinical course and, in a substantial proportion of patients, an aggressive disease behavior requiring timely and effective treatment at diagnosis.
In recent years, the therapeutic landscape of MCL has undergone a major transformation with the introduction of Bruton's tyrosine kinase inhibitors (BTKis). Ibrutinib, acalabrutinib, zanubrutinib, and the non-covalent BTKi pirtobrutinib have demonstrated substantial clinical activity in relapsed/refractry (R/R) MCL. Their role has progressively expanded beyond the relapsed/refractory setting, with BTK inhibitor-based regimens increasingly being incorporated into frontline treatment strategies, supported by emerging clinical trial evidence and reflected in evolving treatment guidelines and clinical practice.
Despite this rapidly evolving treatment landscape, real-world evidence on the use of BTKi-based regimens in the frontline setting remains limited. In particular, data on treatment selection, efficacy, safety, treatment duration, and management of toxicities in routine clinical practice are still scarce.
We therefore propose an observational cohort study to evaluate the clinical impact of previously untreated patients with MCL receiving frontline BTKi-based regimens in routine clinical practice in Italy. The study will assess treatment patterns, effectiveness, safety, and treatment persistence, providing real-world insights into the use of these strategies beyond clinical trials.
Previously untreated patients with Mantle Cell Lymphoma receiving frontline Bruton's Tyrosin Kinase-based treatment in routine clinical practice in Italy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
General Inclusion Criteria:
For the retrospective enrollment group:
In addition to the general inclusion criteria, patients included in the retrospective cohort must meet the following criterion:
● Patients eligible for BTKi-based treatment before the relevant marketing authorization (AIC) in Italy, includingthose treated through off-label use, compassionate use programs, or under Italian Law 648/96, as applicable.
For the prospective enrollment group:
In addition to the general inclusion criteria, patients included in the prospective cohort must meet the following criterion:
● Patients eligible for a BTKi-based regimen in accordance with the EMA-approved indication and the corresponding AIC in Italy.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who had an indication for a BTKi-based regimen before the marketing authorization (AIC) in Italy. This group may include patients treated before the relevant AIC through off-label use, compassionate use programs, or treatment provided under Italian Law 648/96.
Patients eligible for a BTKi-based regimen in accordance with the EMA approved indication and the corresponding AIC in Italy.
Best overall response
Defined according to Lugano 2014 criteria as the best response recorded between the start of therapy and the end of treatment. Overall response rate (ORR) includes complete (CR) and partial response (PR). Patients without response assessment for any reason are considered non-responders.
Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Progression-free survival (PFS)
Defined as the time from the start of BTKi-based treatment to the first documentation of relapse, progression or death from any cause. Patients alive without progression are censored at the date of last disease assessment.
Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Overall survival (OS)
Defined as the time from the start of BTKi-based treatment to death from any cause. Patients alive are censored at the date of last contact.
Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Event-free survival (EFS)
Defined as the time from the start of BTKi-based treatment to progression, death from any cause or initiation of a new anti-lymphoma treatment (NALT) without documented progression.
Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Time to next treatment (TTNT)
Defined as the time from the start of BTKi-based treatment to the initiation of a NALT.
Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Duration of response (DOR)
Defined in responding patients as the time from the first documentation of CR or PR to progression or death from any cause
Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Non-relapse mortality (NRM)
Defined as death without prior relapse or progression
Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
POD24
Defined as relapse or progression within 24 months from diagnosis (early POD) or later than 24 months (late POD)
Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Incidence of adverse events
Incidence of grade 3, 4 and 5 adverse events according to the latest NCI CTCAE version, and of serious adverse events, occurring after the first dose or at any time during therapy.
Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Incidence of deaths
Deaths occurring during treatment, at the end of treatment, and during follow-up, with specific assessment of early deaths (defined as deaths occurring within 3 months from treatment initiation), treatment-related (toxic) deaths, and causes of death (any).
Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Treatment duration
Defined as the time from the start of BTKi-based treatment to permanent discontinuation for any reason.
Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Treatment discontinuation
Incidence and reasons for treatment discontinuation (progression, toxicity, death, patient preference, physician decision, planned completion, other).
Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
Treatment modifications
Frequency and reasons for dose reductions, interruptions and other modifications.
Time frame: From the beginning of the study up to 5 years after last enrolled patient (up 15 years from study beginning)
No study locations are listed for this record.
Start is estimated for Mar 2027; primary completion for Mar 2042, 180 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione Italiana Linfomi - ETS